Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $23000.0.

  • Gyre Therapeutics' Gains from Investment Securities fell 9987.6% to $23000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 9215.99%. This contributed to the annual value of $18.1 million for FY2024, which is 110.87% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Gains from Investment Securities of $23000.0 as of Q3 2025, which was down 9987.6% from $17.8 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Gains from Investment Securities peaked at $18.5 million during Q3 2024, and registered a low of -$4.3 million during Q1 2024.
  • Its 5-year average for Gains from Investment Securities is $7.2 million, with a median of $3.2 million in 2021.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 55435.34% in 2022, then plummeted by 102613.39% in 2024.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Gains from Investment Securities stood at $2.6 million in 2021, then surged by 554.35% to $17.0 million in 2022, then crashed by 77.25% to $3.9 million in 2023, then tumbled by 52.45% to $1.8 million in 2024, then plummeted by 98.75% to $23000.0 in 2025.
  • Its Gains from Investment Securities was $23000.0 in Q3 2025, compared to $17.8 million in Q2 2025 and $17.8 million in Q1 2025.